How to appeal a UnitedHealthcare adult adhd medications denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for adult adhd medications

Cited policy: OptumRx Prior Authorization Guideline — CNS Stimulants and Related Agents (ADHD)

PA required for adults >=18 for most branded stimulants. Documented DSM-5/5-TR diagnosis. For brand: step therapy through generic mixed amphetamine salts IR/ER or generic methylphenidate IR/ER typically required. Quantity limits per FDA label (Vyvanse 70 mg/day, Adderall XR 30 mg/day adults).

How UnitedHealthcare denies adult adhd medications — and how to counter it

Where UnitedHealthcare pushes back: 1) 'ADHD onset must be documented prior to age 7' (using outdated DSM-IV); 2) 'Generic lisdexamfetamine must be tried first' (post Aug 2023); 3) 'Dose exceeds FDA-labeled maximum'; 4) 'No documented trial of non-stimulant first-line agent'.

Counter-arguments that hold up: Cite DSM-5-TR Criterion B (age 12, not 7) verbatim — OptumRx clinical guideline itself references DSM-5. For dose: CADDRA 2024 + Cortese 2018 dose-response; weight-based calculation (Vyvanse 0.5-1.5 mg/kg). Non-stimulant-first contrary to AAFP + Cortese 2018 evidence — stimulants are first-line in adults.

What UnitedHealthcare typically denies for adult adhd medications

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For adult adhd medications, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the adult adhd medications treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Vyvanse
• Adderall XR
• Concerta
• Focalin XR
• Ritalin LA
• Strattera

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.